Giuseppe
Emeritus
[Source: Chest, full page: (LINK). Abstract, edited.]
------
Epidemic of Lung Cancer in Patients With HIV Infection
Tiffany A. Winstone, MD; S. F. Paul Man, MD, FCCP; Mark Hull, MD; Julio S. Montaner, MD, FCCP; Don D. Sin, MD, FCCP
Author and Funding Information: From the Division of Respiratory Medicine (Drs Winstone, Man, and Sin) and Division of AIDS (Drs Hull and Montaner), Department of Medicine, University of British Columbia; and UBC James Hogg Research Center (Drs Man and Sin), Institute for Heart + Lung Health, and British Columbia Centre for Excellence in HIV/AIDs (Drs Hull and Montaner), St. Paul?s Hospital, Vancouver, BC, Canada.
Correspondence to: Don D. Sin, MD, FCCP, St. Paul?s Hospital, 1081 Burrard St, Room 8442, Vancouver, BC, V6Z 1Y6, Canada; e-mail: don.sin@hli.ubc.ca
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.
CHEST. February 2013;143(2):305-314. doi:10.1378/chest.12-1699 - Published online
Abstract
The survival of patients with HIV infection has improved dramatically over the past 20 years, largely owing to a significant reduction in opportunistic infections and AIDs-defining malignancies, such as lymphoma and Kaposi sarcoma. However, with improved survival, patients with HIV are experiencing morbidity and mortality from other (non-AIDs-defining) complications, such as solid organ malignancies. Of these, the leading cause of mortality in the HIV-infected population is lung cancer, accounting for nearly 30% of all cancer deaths and 10% of all non-HIV-related deaths. Importantly, the average age of onset of lung cancer in the HIV-infected population is 25 to 30 years earlier than that in the general population and at lower exposure to cigarette smoke. This article provides an overview of the epidemiology of lung cancer in the HIV-infected population and discusses some of the important risk factors and pathways that may enhance the risk of lung cancer in this population.
-Tiffany A. Winstone, MD; S. F. Paul Man, MD, FCCP; Mark Hull, MD; Julio S. Montaner, MD, FCCP; Don D. Sin, MD, FCCP
Author and Funding Information: From the Division of Respiratory Medicine (Drs Winstone, Man, and Sin) and Division of AIDS (Drs Hull and Montaner), Department of Medicine, University of British Columbia; and UBC James Hogg Research Center (Drs Man and Sin), Institute for Heart + Lung Health, and British Columbia Centre for Excellence in HIV/AIDs (Drs Hull and Montaner), St. Paul?s Hospital, Vancouver, BC, Canada.
Correspondence to: Don D. Sin, MD, FCCP, St. Paul?s Hospital, 1081 Burrard St, Room 8442, Vancouver, BC, V6Z 1Y6, Canada; e-mail: don.sin@hli.ubc.ca
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.
CHEST. February 2013;143(2):305-314. doi:10.1378/chest.12-1699 - Published online
Abstract
The survival of patients with HIV infection has improved dramatically over the past 20 years, largely owing to a significant reduction in opportunistic infections and AIDs-defining malignancies, such as lymphoma and Kaposi sarcoma. However, with improved survival, patients with HIV are experiencing morbidity and mortality from other (non-AIDs-defining) complications, such as solid organ malignancies. Of these, the leading cause of mortality in the HIV-infected population is lung cancer, accounting for nearly 30% of all cancer deaths and 10% of all non-HIV-related deaths. Importantly, the average age of onset of lung cancer in the HIV-infected population is 25 to 30 years earlier than that in the general population and at lower exposure to cigarette smoke. This article provides an overview of the epidemiology of lung cancer in the HIV-infected population and discusses some of the important risk factors and pathways that may enhance the risk of lung cancer in this population.
------